# PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

> **NCT06673017** · PHASE1 · RECRUITING · sponsor: **PanTher Therapeutics** · enrollment: 26 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** PTM-101

## Key facts

- **NCT ID:** NCT06673017
- **Lead sponsor:** PanTher Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-14
- **Primary completion:** 2026-09
- **Final completion:** 2028-06
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06673017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06673017, "PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06673017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*